Stories and Viewpoints

Strengthening our commitment to corporate social responsibility




By: Lara Ramsburg, Head of Corporate Affairs, Viatris


As the world continues to face many challenges, including the continuing impacts of the COVID-19 pandemic, growing disparities in access to healthcare, increasing effects of climate change, and most recently, the crisis in Ukraine, we at Viatris continue to strive to be a valued partner eager to roll up our collective sleeves and make a difference where possible. 

Which is why I am grateful for the opportunity to reflect on our progress and reaffirm our commitment to long-term sustainability following the release of Viatris’ 2021 Sustainability Report.


At Viatris, corporate social responsibility is at the core of our business and purpose. We are committed to sustainability through our efforts that focus on access, the environment, and diversity, equity, and inclusion (DE&I). Our commitment to access to medicine and supporting resilient healthcare systems by advancing sustainable and responsible operations truly is a collective mission, realized through the dedication of colleagues across the organization. 


We’re proud that in our first full year as Viatris, we were able to commit to initial company-wide and multi-year goals, some of which include providing ARV therapy equivalent to a total of 30 million patients, including more than two million children living with HIV/AIDS, between 2022 and the end of 2025. We’ve also committed to impacting 100 million patients via healthcare professional education and outreach regarding prevention, diagnosis, and treatment options for cardiovascular, disease, diabetes, cancer, and other important chronic conditions to improve outcomes through the NCD Academy by the end of 2025. We’re also committing to reducing absolute Scope 1 and 2 greenhouse gas (GHG) emissions 42% by 2030 and reducing Scope 3 GHG emissions covering purchase goods and services, capital goods, fuel, and energy related alternatives, and upstream transportation and distribution 25% by 2030. 


Here are some of Viatris’ key initiatives, progress, and accomplishments in 2021, in collaboration with our partners:

  • Approximately 40% of adults and more than 60% of children being treated for HIV used a Viatris product
  • More than 80 billion doses sold by Viatris across more than 165 countries and territories, reaching approximately 90% of low- and lower-middle-income countries with approximately 7.7 billion doses
  • Established a formal program for building DE&I, beginning with understanding the current makeup of Viatris’ workforce to inform how we will further embed DE&I throughout the organization, support representation, and enhance the employee experience overall
  • Signed on to the UN Global Compact CEO Water Mandate and UN Women’s Empowerment Principles
  • Approximately 500 million doses of medicines donated across a variety of therapeutic areas by working through a trusted network of partners


These goals and accomplishments are only possible through the collective effort of our more than 37,000 colleagues as well as great collaboration and partnership with our internal and external stakeholders. 


We look forward to strengthening the foundation Viatris has built and sharing the progress we make as we continue our mission to empower people worldwide to live healthier at every stage of life, regardless of geography or circumstance. 


Read the full feature story on


You may also like
  • Share this: